We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




An Anti-Inflammatory Agent Could Reverse Spinal Cord Injury Damage

By HospiMedica International staff writers
Posted on 13 Apr 2009
An experimental agent is able to speed recovery and substantially reduce the damage resulting from spinal cord injury by blocking inflammatory reactions, according to a new study. More...


Researchers at Georgetown University Medical Center (GUMC; Washington, DC, USA; gumc.georgetown.edu) tested the glutamate receptor activator (RS)-2-chloro-5-hydroxyphenylglycine (CHPG) so as to selectively activate the group I metabotropic glutamate receptor 5 (mGluR5) found on the surface of microglial cells. Laboratory rats received intrathecal infusion of CHPG for 7 days after moderate impact spinal cord injury (SCI) at T9. Complementary studies examined CHPG effects on activated spinal microglia cultures. The researchers found that functional motor recovery was significantly increased by CHPG treatment up to 28 days after injury, with improvements in weight bearing, step taking, and coordination of stepping behavior. CHPG treatment also significantly reduced lesion volume and increased white matter sparing at 28 days post-injury. The mGluR5 stimulation also reduced microglial activation and decreased microglial-induced neurotoxicity in spinal cord cell cultures, as the immune cells shut down production of the neurotoxins that lead to cell death near the site of injury. The study was published early online on March 26, 2009, in the Annals of Neurology.

"Under certain conditions, like spinal cord injury and brain trauma, microglia become activated," said senior investigator Alan Faden, M.D., Ph.D. "They release toxic chemicals that can kill healthy adjacent tissue, and this process can continue for months. We have found that six months after an injury, the expression of certain inflammatory factors in the spinal cord is 4-5 times normal levels; it has been shown that after human trauma, brain tissue can continue to be lost even more than a year after the injury."

"The findings we have made in this study may potentially be applicable to other neurological disorders, including stroke, head injury, Alzheimer's disease and Parkinson's disease," added Dr. Faden, a professor of neuroscience and director of the laboratory for the study of central nervous system injury at GUMC.

Related Links:
Georgetown University Medical Center



Gold Member
12-Channel ECG
CM1200B
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
ow Frequency Pulse Massager
ET10 L
Absorbable Monofilament Mesh
Phasix Mesh
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The fiber in the brain implant is less than half a millimeter thick (Photo courtesy of Peter Aagaard Brixen)

Brain Implant Records Neural Signals and Delivers Precise Medication

Neurological diseases such as epilepsy involve complex interactions across multiple layers of the brain, yet current implants can typically stimulate or record activity from only a single point.... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.